Viread now also approved to treat hepatitis B
The drug is administered as a once-daily tablet.
The anti-HIV drug Viread (tenofovir disoproxil fumarate, Gilead Sciences) has gained a new indication: to treat chronic hepatitis B in adults. Administered as a once-daily tablet, the drug works by blocking an enzyme required by the hepatitis B virus to replicate in liver cells. Hepatitis B is most prevalent among Asian Americans in this country.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, clickhere.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
